Clinical Trial Update: A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662 [Phase 1]

View source ↗

Summary

A Phase 1 brain imaging study evaluating a single dose of RG1662 in individuals with Down syndrome and healthy controls; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• RG1662

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Healthy Volunteer, Down Syndrome | Phase 1 | Status: COMPLETED